Noticias y Actividades de Sofinnova Partners
Presencia
Sede: Francia
Fusión, adquisición y financiación con participación de Sofinnova Partners.
- Sofinnova Partners acaba de anunciar una recaudación de fondos de 750 millones de dólares. (publicado el 18 de noviembre de 2025).
Ejecutivos
Ver el organigrama con sus 66 ejecutivos principales
Biografías más buscadas en Sofinnova Partners
- Antoine Papiernik, Managing Partner and Chairman of the Board
- Jacques Theurillat, Partner, Crossover Strategy
- Michael Krel, Partner, Industrial Biotechnology Strategy
Crear su alerta
para seguir los movimientos de los ejecutivos en Sofinnova Partners.
Fondo
Sofinnova Partners tiene 1.666 competidores entre los que se incluyen BlackRock (Estados Unidos), KKR (Estados Unidos) y Blackstone Group (Estados Unidos).
Popular M&A news in Fondo
- Lone Star Funds has announced the acquisition of ContiTech (publicado el 17 de julio de 2026).
- Archimed Group ha Esperion Therapeutics adquirido (publicado el 14 de julio de 2026).
- B Capital Group has announced the acquisition of Russell Investments (publicado el 14 de julio de 2026).
Otros contactos sugeridos en el sector Fondo
Noticias
Últimos comunicados de prensa de Sofinnova Partners
- Seven years: the journey behind Myricx's acquisition by Novartis — Sofinnova Partners
- Sofinnova Partners appoints David Evans as Partner — Sofinnova Partners
- Moon Surgical and Uncovr Announce First 20 Clinical Cases of Automated Operative Reporting on Maestro® — Sofinnova Partners
- Sofinnova Partners announces Myricx Bio agrees to be acquired by Novartis — Sofinnova Partners
- Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances — Sofinnova Partners
- Partnership with French cancer research network FFCD expands Bioptimus’s STELA programme — Sofinnova Partners
- Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases — Sofinnova Partners
- How a Sofinnova Partner's thesis became a $165M biotech — Sofinnova Partners
- F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis — Sofinnova Partners
- Germany’s top research institutions and venture capital investors unite behind spin-off framework — Sofinnova Partners
- View more press releases Close
Redes sociales sobre Sofinnova Partners
- Sofinnova Partners en Wikipedia, Google News y Yahoo Finance
- Sofinnova Partners en LinkedIn, Twitter y YouTube
